The Pharma Data

DECEMBER 8, 2020

Laying down a new track for RNA processing, Remix launched with $81 million in financing. Funds will be used to support development of the REMaster technology platform and advance the company’s pipeline of RNA processing targeted therapeutics as well. “As Pear Therapeutics. Most read today on BioSpace: Source link.

RNA 52

RNA Therapies Disease Protein Expression 52

Broad Institute

JUNE 27, 2024

By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. CRISPRoff uses building blocks from CRISPR gene editing technology, including the guide protein Cas9 that directs the tool to the target gene.

Disease 142

Disease Therapies Clinical Trials Engineering 142

Drug Target Review

MAY 22, 2024

What are the key findings of Circio’s in vivo proof-of-concept for its circVec circular RNA platform technology compared to conventional mRNA-based expression with DNA vectors? Circular RNA (circRNA) has two major advantages versus mRNA in a vector-expression context. DNA vectors in mouse models?

Therapies 59

Therapies RNA Protein Expression DNA 59